| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006840 |
| Receipt No. | R000008075 |
| Official scientific title of the study | Research of gemcitabine sensitivity in pancreatic cancer. |
| Date of disclosure of the study information | 2011/12/08 |
| Last modified on | 2016/06/08 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Research of gemcitabine sensitivity in pancreatic cancer. | |
| Title of the study (Brief title) | Research of gemcitabine sensitivity in pancreatic cancer. | |
| Region |
|
|
| Condition | ||
| Condition | Advanced pancreatic cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We will observe the relationship between the level of phosphorylated heat shock protein 27 (HSP27) obtained from human pancreatic cancer by EUS-FNA and the sensitivity to gemcitabine (GEM) in order to find god prognostic marker. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Response rate and prognosis of chmotherapy with GEM. |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Chemotherapy including gemcitabine. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Advanced pancreatic cancer diagnosed by EUS-FNA. | |||
| Key exclusion criteria | Advanced pancreatic cancer could not be diagnosed by EUS-FNA. | |||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Ichiro Yasuda |
| Organization | Gifu University |
| Division name | Dept. of Gastroenterology |
| Address | 1-1 Yanagido, Gifu 501-1194, Japan |
| TEL | 058-230-6308 |
| yasudaic@gmail.com | |
| Public contact | |
| Name of contact person | Ichiro Yasuda |
| Organization | Gifu University |
| Division name | Dept. of Gastroenterology |
| Address | 1-1 Yanagido, Gifu 501-1194, Japan |
| TEL | 058-230-6308 |
| Homepage URL | |
| yasudaich@gmail.com | |
| Sponsor | |
| Institute | Gifu University
Dept. of Gastroenterology |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Ministry of Education, Culture, Sports, Science and Technology of Japan. |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000008075 |